[Cancer gene therapy with plasmid expressing anti-HER2/neu-toxin]

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• The HER2/neu receptor is frequently over-expressed in various cancers.
• Targeted drug delivery systems are crucial for effective cancer therapy.
• Developing specific targeting molecules for cancer treatment is an active area of research.

Purpose of the Study:

• To engineer a novel construct for targeted cancer therapy.
• To evaluate the efficacy of a Pseudomonas toxin fragment (PE40) linked to a HER2/neu-specific DARPin molecule.
• To assess the in vitro and in vivo anti-tumor activity of the engineered construct.

Main Methods:

• Genetic engineering of a construct expressing PE40 fused with a DARPin molecule targeting HER2/neu.
• In vitro evaluation of the construct's cytotoxicity against transfected tumor cells.
• In vivo studies involving intra-tumor injections of the construct complexed with polyethyleneimine in a mouse tumor model (D2F2/E2).

Main Results:

• The engineered construct demonstrated high specificity for the HER2/neu receptor.
• Transfected tumor cells were destroyed by the construct in vitro.
• Intra-tumor administration of the construct led to significant growth retardation of D2F2/E2 tumors in mice.

Conclusions:

• The HER2/neu-targeted PE40-DARPin construct shows promise as a novel anti-cancer therapeutic agent.
• This approach offers a potential strategy for developing targeted therapies against HER2/neu-overexpressing cancers.
• Further research is warranted to explore the clinical applicability of this engineered toxin delivery system.